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implemented. The FDA is com­
mitted  to  pursuing  these  an­
swers with the medical and sci­
entific communities and will take 
the steps necessary to ensure that 
the benefits of anesthetic use in 
children  continue  to  outweigh 
any potential risks.
Disclosure forms provided by the authors 
are available with the full text of this arti­
cle at NEJM.org.
From the Division of Anesthesia and Anal-
gesia Products, Office of New Drugs (B.R., 
R.D.M., A.S.) and the Center for Drug Evalu-
ation and Research (J.W.), Food and Drug 
Administration, Silver Spring, MD.
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Defining Safe Use of Anesthesia in Children
T
he pain and disability caused 
by osteoporotic vertebral frac­
tures  have  long  motivated  the 
search for effective therapy. Two 
procedures  designed  to  restore 
vertebral body height and func­
tion have been widely adopted: 
percutaneous  vertebroplasty,  in 
which  cement  is  injected  into 
the vertebral body to support the 
fractured bone; and kyphoplasty, 
a  variant  of  vertebroplasty  in 
which a balloon is inserted and 
inflated in a collapsed vertebral 
body, restoring the bone’s height 
before the cement injection. Ini­
tial studies suggested that these 
procedures were superior to con­
ventional symptomatic treatment. 
But when later studies cast doubt 
on  those  favorable  findings, 
health  care  funding  agencies 
sought  to  curb  their  use.  The 
story of these procedures offers 
a glimpse of the ways in which 
comparative­effectiveness research 
(CER)  may  influence  medical 
practice and health care expen­
ditures.
Early studies of these proce­
dures  were  neither  randomized 
nor  blinded,  and  because  the 
symptoms of compression frac­
tures often abated over time, the 
lack of adequate controls made it 
impossible to know whether im­
provements that followed treat­
ment would have occurred even 
without  surgery.  Furthermore, 
neither procedure was risk­free; 
reported complications included 
compression  fractures,  cement 
leakage,  pulmonary  complica­
tions, paraplegia, and death.1 In 
a scenario that’s likely to be re­
peated frequently as CER gains 
greater acceptance and support, 
randomized trials eventually fol­
lowed the observational studies 
that had fostered the initial en­
thusiasm.2  If  the  full  conse­
quences of that research are not 
yet fully apparent, their potential 
importance is. Were the results 
of better­designed studies trans­
lated into practice, the reduction 
in U.S. health care expenditures 
would be considerable.
CER treats effectiveness as a 
balance of benefits and harms; 
when the risks associated with a 
procedure  outweigh  its  clinical 
benefits,  it  is  appropriate  and 
ethical to limit its use. Both the 
clinical need and the desire to 
avoid wasteful expenditures were 
part of the rationale for subject­
ing these procedures to compar­
ative studies. Furthermore, con­
sensus that these procedures were 
promising but unproven led sev­
eral  countries  to  make  them 
available on an interim­coverage 
basis. These arrangements, in ef­
fect from 2006 through 2010, al­
lowed the procedures to be per­
formed in everyday practice while 
further evidence was generated.
Trials conducted during that 
period suggested that kyphoplasty 
did  not  improve  outcomes.  The 
studies of vertebroplasty produced 
varying results, but the highest­
quality trials cast doubt on the 
benefit  and  raised  additional 
safety concerns. In a randomized 
but non­blinded trial by Kallmes 
et  al.,3  patients  who  underwent 
vertebroplasty  and  controls  had 
similar  reductions  in  disability 
and pain scores, with a trend to­
ward a higher rate of clinically 
meaningful improvement in pain 
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(30% decrease from baseline) in 
the  vertebroplasty  group  that 
neared  statistical  significance 
(64% vs. 48%, P = 0.06). In a ran­
domized, blinded trial by Buch­
binder et al.,4 vertebroplasty did 
not have a statistically significant 
advantage  over  placebo  in  any 
measured outcome over 6 months, 
although pain diminished in both 
groups.
These studies illustrate the dif­
ficulty of inferring the effects of 
treatments for a condition with a 
variable time course, particular­
ly  when  its  manifestations  are 
strongly  influenced  by  placebo 
effects.  But  the  studies  at  best 
cast doubt on the magnitude of 
any  benefits  from  these  proce­
dures  and  at  worst  established 
their  ineffectiveness.  The  find­
ings led U.S. and other payers to 
revisit their interim funding de­
cisions.  To  improve  safety  and 
quality and to respond to pres­
sures for fiscal responsibility and 
efficiency  in  health  care,  payers 
are deciding to limit or withdraw 
coverage for these procedures. In 
late  2010,  the  Blue  Cross  Blue 
Shield Association’s Medical Ad­
visory  Panel  confirmed  its  deci­
sion  that  neither  procedure  met 
its  criteria  for  established  effec­
tiveness, and in Canada, the On­
tario Health Technology Advisory 
Committee  ruled  that  vertebro­
plasty should not be considered 
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Medicare (NIS) Vertebroplasty 11,253 (82.2) 11,411 128,407,983 64,203,992 102,726,386
Kyphoplasty 19,397 (82.7) 14,336 278,075,392 139,037,696 222,460,314
Medicare (SASD) Vertebroplasty 6,260 (77.7) 4,451 27,863,260 13,931,630 22,290,608
Kyphoplasty 11,684 (76.2) 7,328 85,620,352 42,810,176 68,496,282
Medicare total (NIS + SASD) Vertebroplasty 17,513 (80.5) — 156,271,243 78,135,622 125,016,994
Kyphoplasty 31,081 (80.1) — 363,695,744 181,847,872 290,956,595
Private insurance (NIS) Vertebroplasty 1,522 (11.1) 14,514 22,090,308 11,045,154 17,672,246
Kyphoplasty 2,992 (12.8) 11,968 35,808,256 17,904,128 28,646,604
Private insurance (SASD) Vertebroplasty 1,341 (16.6) 4,865 6,523,965 3,261,983 5,219,172
Kyphoplasty 2,913 (18.9) 9,945 28,969,785 14,484,893 23,175,828
Private insurance total (NIS + SASD) Vertebroplasty 2,863 (13.2) — 28,614,273 14,307,137 22,891,418
Kyphoplasty 5,905 (15.2) — 64,778,041 32,389,021 51,822,433
Combined total of principal 
  procedures
— 57,362 (94.8) — 613,359,301 306,679,652 490,687,440
Medicare, secondary procedure (NIS) Vertebroplasty 3,024 11,411 34,506,864 17,253,432 27,605,491
Kyphoplasty 14,932 14,336 214,065,152 107,032,576 171,252,122
Private insurance, secondary 
  procedure (NIS)
Vertebroplasty 653 14,514 9,477,642 4,738,821 7,582,114
Kyphoplasty 2,979 11,968 35,652,672 17,826,336 28,522,138
Grand Total, Principal + Secondary — 78,950 — 907,061,631 453,530,817 725,649,305
* Data are from the 2008 Nationwide Inpatient Sample (NIS) and the State Ambulatory Surgery Databases (SASD) of the Healthcare Cost 
and Utilization Project, Agency for Healthcare Research and Quality (AHRQ).5 Complete SASD data were analyzed and provided by Claudia 
Steiner of AHRQ. Primary procedures not paid for by Medicare or private insurance were provided to patients with Medicaid or no insur-
ance. The estimates of budget impact are conservative, in part because we used costs (as reported to the Centers for Medicare and 
Medicaid Services) instead of charges or actual payments, and in part because the SASD covers only 28 states. We conservatively estimate 
that 17,000 (80%) of the NIS procedures coded as secondary were actually the major procedure performed; SASD coded fewer than 3000 
procedures as secondary, and these have been excluded from the analysis.
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the standard treatment for osteo­
porotic vertebral fractures.
Any  CER  agenda  strives  for 
improved  safety  and  quality  of 
care. By identifying relative inef­
fectiveness,  CER  may  also  im­
prove the health care system by 
freeing up resources to be used 
for safer and more effective forms 
of care. Savings from limiting the 
use  of  care  whose  effectiveness 
is unproven can be substantial, 
whether the intervention is new 
or has already been disseminated. 
According to our analyses of data 
from  the  Healthcare  Cost  and 
Utilization  Project,5  in  2008  the 
cost of kyphoplasty and vertebro­
plasty was approximately $1 bil­
lion. The table shows the estimat­
ed savings in the United States, 
by insurance type, under alterna­
tive  assumptions  about  reduc­
tions in utilization. A 50% reduc­
tion in utilization would deliver 
annual savings of $450 million; 
an  80%  reduction  would  save 
about $725 million annually. Since 
these figures are based on costs 
rather than charges or payments, 
they are highly conservative. And 
although  these  figures  appear 
small relative to U.S. health care 
expenditures, the procedures are 
not  among  the  most  common. 
Furthermore, savings are large in 
relation  to  the  $1.1  billion  that 
Congress allocated to CER in the 
2009 American Recovery and Re­
investment Act. When the Patient­
Centered Outcomes Research In­
stitute, created by the Affordable 
Care  Act  (ACA),  is  fully  opera­
tional, its budget is expected to 
reach $500 million annually, or 
just two thirds of the potential 
savings  each  year  from  dimin­
ished use of just two apparently 
ineffective procedures.
The savings might be reduced 
if patients who don’t receive one 
of these procedures end up being 
treated  more  aggressively  with 
other forms of care. For example, 
patients who do not undergo ver­
tebroplasty  might  receive  more 
pain medications or physical ther­
apy  than  patients  who  undergo 
the procedure. However, such off­
sets in savings would be substan­
tial only if the procedures greatly 
diminish  symptoms  for  an  ex­
tended  period.  Furthermore,  the 
cost­savings  estimates  don’t  take 
into account expenditures for the 
treatment of adverse effects of the 
procedures.
CER won’t always yield defini­
tive conclusions about a therapy’s 
effectiveness; individual patients 
might benefit despite disappoint­
ing results in randomized trials. 
But the adoption of a procedure 
in routine practice, if not part of 
a  well­designed  study,  probably 
won’t reveal the characteristics of 
the  patients  likely  to  benefit.  If 
observational studies are well de­
signed and build on clinically de­
tailed data, they can often eluci­
date information about subgroups 
that were not studied in a trial. 
But the limitations of convention­
al observational studies for a con­
dition with fluctuating symptoms 
and whose main manifestation is 
pain apply here: without double 
blinding  and  closely  matched 
controls, it will be surpassingly 
difficult to distinguish the effects 
of the intervention from the nat­
ural  history  of  the  condition. 
Thus, without randomized trials, 
ineffective and costly treatments 
with  risks  and  complications 
would  continue  to  be  adminis­
tered largely because the alterna­
tive  treatments  are  disappoint­
ing. If nothing else, well­designed 
studies demonstrating ineffective­
ness  can  help  redirect  research 
toward the development of alter­
natives.
Of course, savings will be de­
rived  from  CER  only  if  practice 
changes. In the United States, it’s 
unclear whether these studies are 
powerful enough to overturn cov­
erage decisions or cut utilization 
of  established  procedures.  The 
status quo plays a large role in de­
termining the burden of proof for 
interventions: if a procedure has 
spread widely, large, well­designed 
studies must show that it’s clearly 
ineffective or harmful before pay­
ers and providers will abandon it; 
for a new procedure, the assump­
tion is that effectiveness has not 
been established, so good studies 
demonstrating  effectiveness  are 
required for its adoption. Increas­
ingly, funding agencies and poli­
cymakers  aim  to  subject  estab­
lished practices to greater scrutiny, 
since often interventions adopted 
without strong evidence are later 
found to be ineffective or not as 
effective as initially thought.
ACA features such as bundled 
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payments,  shared  savings  pro­
grams, and outcomes­based pay­
ments offer mechanisms for stim­
ulating the adoption of practices 
that  are  supported  by  CER  and 
the abandonment of practices that 
CER calls into question. The ben­
efits for patients are large, as are 
the potential savings. Support for 
CER,  reinforced  by  appropriate 
payment changes, is likely to rep­
resent a very good investment for 
the federal government and U.S. 
taxpayers.
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